Skip to main content

Table 2 The results of univariate analysis

From: Eosinophil-to-monocyte ratio is a potential biomarker in the prediction of functional outcome among patients with acute ischemic stroke

Characteristics Poor outcome p value
No Yes
Age, years, mean (SD) 66.90 ± 12.68 74.17 ± 13.09 < 0.001
Female, (%) 140 (41.18%) 92 (50.83%) 0.035
Hypertension, (%) 285 (83.82%) 160 (88.40%) 0.159
Diabetes, (%) 77 (22.65%) 50 (27.62%) 0.208
Hyperlipidemia, (%) 147 (43.24%) 62 (34.25%) 0.046
Previous stroke, (%) 49 (14.41%) 47 (25.97%) 0.001
Coronary heart disease, (%) 20 (5.88%) 31 (17.13%) < 0.001
Atrial fibrillation, (%) 29 (8.53%) 57 (31.49%) < 0.001
Current cigarette smoking, (%) 33 (9.71%) 21 (11.60%) 0.499
NIHSS, median (IQR) 2 (1–3) 7.00 (4–11) < 0.001
Premorbid mRS score, median (IQR) 0 (0–0) 0 (0–0) 0.065
Stroke subtypes < 0.001
 Large artery atherosclerosis 108 (31.76%) 80 (44.20%)  
 Cardioembolic stroke 25 (7.35%) 52 (28.73%)  
 Small artery disease 201 (59.12%) 49 (27.07%)  
 Other etiology/unknown 6 (1.76%) 0 (0.00%)  
IV rtPA, (%) 29 (8.53%) 16 (8.84%) 0.904
Proton pump inhibitors 106 (31.18%) 107 (59.12%) < 0.001
Triglyceride, mmol/L, median (IQR) 1.46 (1.02–2.03) 1.21 (0.94–1.67) 0.001
Total cholesterol, mmol/L, mean (SD) 4.91 ± 1.45 4.94 ± 1.15 0.765
High-density lipoprotein cholesterol, mmol/L, mean (SD) 1.29 ± 0.37 1.33 ± 0.38 0.289
Low-density lipoprotein cholesterol, mmol/L, mean (SD) 2.46 ± 0.74 2.50 ± 0.74 0.577
EMR, median (IQR) 0.22 (0.10–0.39) 0.12 (0.05–0.23) < 0.001
  1. EMR eosinophil-to-monocyte ratio, IQR interquartile range, IV rtPA intravenous recombinant tissue plasminogen activator, NIHSS National Institutes of Health Stroke Scale